XML 24 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies
12 Months Ended
Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]

10. Commitments and Contingencies

 

Commitments

 

The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through February 2015. Total minimum lease payments, including scheduled increases, are charged to operations on the straight-line basis over the life of the respective lease. Rent expense was approximately $548,000, $558,000, and $534,000 in 2011, 2010 and 2009, respectively.

 

At December 31, 2011, minimum commitments remaining under lease agreements were approximately as follows:

 

    Amount  
Years Ending December 31:        
2012   $ 605,000  
2013     584,000  
2014     577,000  
2015     519,000  
2016     13,000  
Thereafter      
    $ 2,298,000  

 

Purchase Commitment

 

The Company has a supply agreement with a vendor which requires the Company to purchase isotopes used in its drug testing procedures from this sole supplier in exchange for variable annual payments based upon prior year purchases. Purchases amounted to $527,477, $431,897, and $584,109 in 2011, 2010, and 2009, respectively. The Company expects to purchase approximately $610,000 in 2012. In exchange for exclusivity, the supplier has provided the Company with the right to purchase the isotope technology at fair market value under certain conditions, including the failure to meet the Company’s purchase commitments. This agreement does not include a fixed termination date; however, it is cancelable upon mutual agreement by the parties or six months after termination notice by the Company of its intent to use a different technology in connection with its drug testing procedures.

 

Contingencies

 

The Company is subject to legal proceedings and claims, which arise in the ordinary course of its business. The Company believes that although there can be no assurance as to the disposition of these proceedings, based upon information available to the Company at this time, the expected outcome of these matters would not have a material impact on the Company’s results of operations or financial condition.